Corrects headline and story to say the treatment will be launched in 2025, not 2026
March 10 (Reuters) - Eli Lilly LLY.N plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday.
"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the Leerink Partners Global Healthcare Conference.
Global demand for Lilly's and Danish rival Novo Nordisk's NOVOb.CO diabetes and weight-loss drugs has been extraordinary, with the two companies delaying their entry into new and emerging markets until they scaled up supply.
Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes and weightloss. However, it is sold under the brand name Zepbound for obesity in the U.S.
The drug received approval from Chinese regulators last year.
In February last year, Lilly CEO David Ricks told Reuters that it expects to launch Mounjaro, in India as early as next year.
(Reporting by Sriparna Roy and Christy Santhosh in Bengaluru; Editing by Leroy Leo)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。